Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Net Income towards Common Stockholders: 2015-2024

Historic Net Income towards Common Stockholders for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to -$126.9 million.

  • UroGen Pharma's Net Income towards Common Stockholders fell 40.87% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.6 million, marking a year-over-year decrease of 42.70%. This contributed to the annual value of -$126.9 million for FY2024, which is 24.09% down from last year.
  • Latest data reveals that UroGen Pharma reported Net Income towards Common Stockholders of -$126.9 million as of FY2024, which was down 24.09% from -$102.2 million recorded in FY2023.
  • UroGen Pharma's 5-year Net Income towards Common Stockholders high stood at -$102.2 million for FY2023, and its period low was -$128.5 million during FY2020.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$109.8 million (2022), whereas its average is -$113.0 million.
  • Per our database at Business Quant, UroGen Pharma's Net Income towards Common Stockholders rose by 13.75% in 2021 and then decreased by 24.09% in 2024.
  • UroGen Pharma's Net Income towards Common Stockholders (Yearly) stood at -$128.5 million in 2020, then climbed by 13.75% to -$110.8 million in 2021, then rose by 0.94% to -$109.8 million in 2022, then rose by 6.87% to -$102.2 million in 2023, then dropped by 24.09% to -$126.9 million in 2024.